GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $1,021,160.89 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,559 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $96.71, for a total transaction of $1,021,160.89. Following the sale, the chief executive officer now directly owns 14,865 shares in the company, valued at approximately $1,437,594.15. This trade represents a 41.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The shares were sold at an average price of $89.44, for a total transaction of $96,416.32.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Performance

GeneDx stock opened at $97.44 on Thursday. GeneDx Holdings Corp. has a 1-year low of $8.03 and a 1-year high of $115.60. The firm has a market cap of $2.73 billion, a P/E ratio of -49.71 and a beta of 1.91. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average of $84.59 and a 200-day moving average of $70.97.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Sell-side analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on WGS shares. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

Institutional Investors Weigh In On GeneDx

Several hedge funds have recently made changes to their positions in the company. MCF Advisors LLC lifted its position in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after acquiring an additional 182 shares during the period. Sterling Capital Management LLC raised its stake in GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after buying an additional 316 shares during the last quarter. Global Retirement Partners LLC bought a new stake in GeneDx in the fourth quarter worth $28,000. Lazard Asset Management LLC purchased a new stake in shares of GeneDx in the fourth quarter worth $35,000. Finally, Comerica Bank bought a new position in shares of GeneDx during the fourth quarter valued at $50,000. 61.72% of the stock is currently owned by institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.